Login
Evidence Feed
About
Diagnostics
New
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
DRUG:
Elyxyb (celecoxib)
i
Other names:
DFN15, DFN-15, DFN-15A, DFN-15B
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Associations
(3)
News
Trials
Company:
Collegium Pharma, Dr. Reddy’s, Sorrento
Drug class:
COX2 inhibitor
Related drugs:
‹
amlodipine/celecoxib (1)
parecoxib (1)
DRGT-46 (1)
CA102N (0)
apricoxib (0)
ECP-1014 (0)
celecoxib oral (0)
ETS2101 (0)
VT-11CR (0)
amlodipine/celecoxib (1)
parecoxib (1)
DRGT-46 (1)
CA102N (0)
apricoxib (0)
ECP-1014 (0)
celecoxib oral (0)
ETS2101 (0)
VT-11CR (0)
›
Associations
(3)
News
Trials
Filter by
Latest
1m
RECON: Celecoxib, Durvalumab and Tremelimumab for the Treatment of Patients With Advanced or Metastatic Liver Cancer (clinicaltrials.gov)
P2, N=39, Not yet recruiting, Emory University | Trial completion date: Nov 2026 --> Nov 2027 | Trial primary completion date: Nov 2025 --> Nov 2026
1 month ago
Trial completion date • Trial primary completion date
|
Imfinzi (durvalumab) • Imjudo (tremelimumab-actl) • Elyxyb (celecoxib) • celecoxib oral
3ms
Celecoxib, Durvalaumab and Tremellimumab for the Treatment of Patients With Advanced or Metastatic Liver Cancer (clinicaltrials.gov)
P2, N=39, Not yet recruiting, Emory University
3 months ago
New P2 trial
|
Imfinzi (durvalumab) • Imjudo (tremelimumab-actl) • Elyxyb (celecoxib) • celecoxib oral
5ms
Methotrexate, Erlotinib, and Celecoxib for the Treatment of Recurrent/Metastatic Oral Cavity Cancer in a Rural Midwest United States Population (clinicaltrials.gov)
P2, N=25, Recruiting, Mayo Clinic | Not yet recruiting --> Recruiting
5 months ago
Enrollment open
|
erlotinib • methotrexate • Elyxyb (celecoxib) • celecoxib oral
5ms
Methotrexate, Erlotinib, and Celecoxib for the Treatment of Recurrent/Metastatic Oral Cavity Cancer in a Rural Midwest United States Population (clinicaltrials.gov)
P2, N=25, Not yet recruiting, Mayo Clinic | Initiation date: Jun 2025 --> Sep 2025
5 months ago
Trial initiation date
|
erlotinib • methotrexate • Elyxyb (celecoxib) • celecoxib oral
6ms
Methotrexate, Erlotinib, and Celecoxib for the Treatment of Recurrent/Metastatic Oral Cavity Cancer in a Rural Midwest United States Population (clinicaltrials.gov)
P2, N=25, Not yet recruiting, Mayo Clinic
6 months ago
New P2 trial
|
erlotinib • methotrexate • Elyxyb (celecoxib) • celecoxib oral
Share via
^
^
×
Unlock More with VERI
Sign up to access premium content
Email *
Password *
Confirm Password *
I'm not a robot
Please register with your email ID.
×
Unlock More with VERI
Sign up to access premium content
Email *
Password *
Confirm Password *
I'm not a robot
Please register with your email ID.